Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits
Open accessThe DOI matches its Crossref record; 118 of the 119 references it cites were found in a registry or an index; 79 of the 180 sources its claims cite were checked for support.
Abstract
The legalization of cannabis for medical and recreational purposes has progressed internationally. Chronic patterns of cannabis use have been associated with disrupted learning, impaired cognitive performance, reduced educational attainment, cannabis use disorder, psychosis/schizophrenia, mood and anxiety disorders, and suicidal behaviors among adolescents and young adults.
Overview
CoChat Summary
TL;DR
This 2024 review summarizes evidence that recreational cannabis use, especially frequent high-THC use, is linked to acute impairment and several longer-term mental and physical health risks, while medical cannabinoid benefits are limited to a few indications. The strongest therapeutic evidence is for CBD in refractory epilepsy, with smaller benefits for spasticity, chronic pain, and chemotherapy-induced nausea/vomiting.
Key findings
- The review states that regular use of high-THC products can produce cannabis use disorder (CUD), and that 22% of people who ever use cannabis meet criteria for CUD, rising to 33% among weekly or daily users.
- Acute consumption of high THC doses can cause time-limited mental, gastrointestinal, and cardiovascular problems and motor vehicle accidents; the paper reports traffic-accident odds ratios ranging from 1.25 to 1.97.
- For psychosis, meta-analyses found a robust association with cannabis use and a dose–response relationship; one multinational study reported that daily use of high-potency cannabis increased psychosis risk fivefold versus non-users, while daily low-potency use doubled risk.
- For medicinal use, the paper says cannabinoids have small beneficial effects for muscle spasticity, limited/inconsistent evidence for chronic pain, higher antiemetic effects than placebo or conventional anti-emetics for CINV, and that CBD is moderately efficacious for refractory epilepsy in Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex.
Methods
- The paper is a selective literature review intended to update a prior systematic literature search on “benefits and risks of cannabinoids” commissioned by the German Ministry of Health.
- Searches were conducted in PubMed and the Cochrane Central Register of Clinical Trials for 10.5.2016 to 10.5.2023, prioritizing systematic reviews and meta-analyses from the past decade; when unavailable, the authors included strong, adequately powered studies published since the most recent review.
- The references of included studies were screened for additional relevant studies, and the authors used the causal-inference approach outlined in their Text Box 1.
Limitations
- The authors explicitly note that the literature is sparse for some questions, including increased cannabis potency and its effects, and that more rigorous data is needed on outcomes associated with potency, product diversity, and new routes of administration.
- They state that confounding by tobacco and other drug use complicates interpretation of long-term harms, and that case-control and cohort studies are subject to unmeasured confounding.
- Evident from the text: the review is selective rather than a full systematic review of all cannabis evidence, and much of the therapeutic literature is described as limited, heterogeneous, or insufficient for guidance.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
68 Valid · 3 Not valid · 68 Not checked · 39 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Acute cannabis consumption has consistently been associated with a modest increase in the risk of traffic accidents, with odd ratios ranging from 1.25 to 1.97 [17].”
§ Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits > Results > Risks of recreational cannabis use
What the sources say
- Partly supportedcites [17] Preuss UW, Huestis MA, Schneider M et al (2021) Cannabis use and car crashes: a review. Front Psychiatry 12:643315. https://doi.org/10.3389/fpsyt.2021.643315 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says acute cannabis use increases car-crash risk and describes the increase in meta-analytic odds ratios as slight. The Results of Meta-Analyses (page unavailable) report an adjusted OR of 1.25 and an OR of 1.97 for the blood-analysis subgroup, but do not present 1.25–1.97 as the overall range; other reported estimates exceed it. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, there are no reliable cut-off values for blood THC levels that indicate when an individual is impaired.”
§ Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits > Results > Risks of recreational cannabis use
What the sources say
- Supportedcites [24] Pearlson GD, Stevens MC, D’Souza DC (2021) Cannabis and driving. Front. Psychiatry 12:689444. https://doi.org/10.3389/fpsyt.2021.689444 source
The Discussion (page not provided) says there is no straightforward way to equate blood THC levels with current driving impairment. The Recommendations likewise say that detectable blood THC levels are not a useful standard and that meaningful thresholds lack evidence-based consensus. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Growing evidence indicates that dysregulation of ECS may contribute to brain dysfunction, psychopathology, neurodevelopmental problems, neurodegenerative diseases, neuroinflammation, among other physiological functions [9, 10].”
§ Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits > Introduction
What the sources say
- Partly supportedcites [9] Lu HC, Mackie K (2016) An introduction to the endogenous cannabinoid system. Biol Psychiatry 79(7):516–525. https://doi.org/10.1016/j.biopsych.2015.07.028 sourceExperimental — accuracy not yet measured
The Introduction links ECS perturbations to psychiatric disorders, and the LTD section suggests that disrupted cannabinoid signaling could contribute to developmental abnormalities. The Endocannabinoid degradation section links loss of an enzyme involved in endocannabinoid metabolism to a neurodegenerative syndrome. The Cannabinoid receptors section describes changes in CB2 expression during inflammation, but does not establish that ECS dysregulation contributes to neuroinflammation. Page numbers were not available in our copy. (LLM, conf=0.84)
- Partly supportedcites [10] Lowe H, Toyang N, Steele B, Bryant J, Ngwa W (2021) The endocannabinoid system: a potential target for the treatment of various diseases. Int J Mol Sci 22(17):9472. https://doi.org/10.3390/ijms22179472 sourceExperimental — accuracy not yet measured
The Introduction (§1.1; page unavailable) links the ECS to nervous function, neurogenesis, pre- and post-natal development, and neuropsychological and neurodegenerative diseases. The Neurological/Neurodegenerative Diseases section (§3; page unavailable) also implicates the ECS in neurological pathology and describes cannabinoid modulation of neuroinflammation. The paper does not establish that ECS dysregulation contributes to every listed outcome, particularly neurodevelopmental problems or neuroinflammation. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Research is showing that there are some individuals who use cannabis to reduce symptoms of mood or anxiety disorders [40].”
§ Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits > Results > Risks of recreational cannabis use
What the sources say
- Supportedcites [40] Beletsky A, Liu C, Lochte B, Samuel N, Grant I (2024) Cannabis and anxiety: a critical review. Med Cannabis Cannabinoids 7(1):19–30. https://doi.org/10.1159/000534855 source
The Introduction’s table reports that people with lifetime depression used cannabis for self-medication and that some chronic users reported anxiety-related symptom relief. It also states that cannabis is used by some chronic users seeking to alleviate anxiety. This supports the claim about why some individuals use it, without establishing that it effectively treats those disorders. (LLM, conf=0.91)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“There is partial support from longitudinal studies for a causal link between cannabis use and a reduction in motivation, that has been referred to as an “a motivation syndrome” [31].”
§ Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits > Results > Risks of recreational cannabis use
What the sources say
- Supportedcites [31] Pacheco-Colón I, Limia JM, Gonzalez R (2018) Nonacute effects of cannabis use on motivation and reward sensitivity in humans: a systematic review. Psychol Addict Behav 32(5):497–507. https://doi.org/10.1037/adb0000380 source
The Discussion concludes that two longitudinal studies provide evidence of a causal relationship between cannabis use and reduced motivation and reward sensitivity. It also describes the broader evidence for an “amotivational syndrome” as equivocal, consistent with the citing sentence’s qualified wording. (LLM, conf=0.94)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
124 more claims · 46 with their cited sources checked
Create a free account to see all 178 claims and to verify the 18 references still open.
- It may state two separate claims as one. 40
- Probably not a substantial claim. 13
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
(2012) · SpringerReference · doi:10.1007/springerreference_121117 · Cited by 20,570
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
(2013) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/103.1437-1588 · Cited by 11,796
The environment and disease: association or causation?
Hill, A. B. (2015) · Journal of the Royal Society of Medicine · doi:10.1177/0141076814562718 · Cited by 7,285
The Environment and Disease: Association or Causation?
Hill, A. B. (1965) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591576505800503 · Cited by 6,974
International Statistical Classification of Diseases and Related Health Problems
(2011) · Encyclopedia of Clinical Neuropsychology · doi:10.1007/978-0-387-79948-3_3055 · Cited by 4,151
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169 · cited 4×
“Mild to moderate central nervous or gastro-intestinal side effects are more common with cannabinoids than with placebo but severe side effects are rare [13].”
InfluentialNeurobiologic advances from the brain disease model of addiction
Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1511480 · Cited by 2,008 · cited 1×
“Case–control neuroimaging studies of the brain with high-resolution provide early evidence for altered brain integrity in brain regions with a high density of CB1 receptors in heavy cannabis users [75].”
Self-citationDegenhardt, L., Charlson, F., Ferrari, A., Santomauro, D., Erskine, H., Mantilla-Herrara, A., Whiteford, H., Leung, J., Naghavi, M., Griswold, M., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30337-7 · Cited by 1,572 · cited 1×
“Worldwide, 22 million people are estimated to meet criteria for CUD, similar in number to opioid use disorders (27 million people) [56].”
Self-citationInternational statistical classification of diseases and related health problems. Tenth revision.
Brämer, G. R. (1988) · PubMed · Cited by 1,492
Groce, E. (2018) · Journal of Medical Regulation · doi:10.30770/2572-1852-104.4.32 · Cited by 1,330
Research works printed but not linked: 1
- Hoch E, Friemel C, Schneider M (2019) Cannabis: benefits and risks. Springer, Heidelberg
Cited by
The adverse public health effects of non-medical cannabis legalisation in Canada and the USA
Mekonen, T., Hoch, E., Fischer, B., Dawson, D., & Hall, W. (2025) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00299-8 · Cited by 51
Self-citationWilson, J., Dobson, O., Langcake, A., Mishra, P., Bryant, Z., Leung, J., Dawson, D., Graham, M., Teesson, M., Freeman, T. P., et al. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00015-5 · Cited by 48
“However, few reviews included evidence for the treatment of all mental disorders and SUDs as the primary indication, 10,11 conducted metaanalyses, 11,14 critically evaluated the risk of bias and quality of evidence, 13,14 or examined the evidence according to the type of cannabinoid.”
Self-citationRamer, R., & Hinz, B. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108851 · Cited by 18
Cannabinoids in Chronic Pain: Clinical Outcomes, Adverse Effects and Legal Challenges
Sič, A., George, C., Gonzalez, D. F., Tseriotis, V., & Knežević, N. N. (2025) · Neurology International · doi:10.3390/neurolint17090141 · Cited by 16
“Rates of dizziness reach 25%, drowsiness 8%, and disorientation 4%, with up to 12% of patients discontinuing treatment due to side effects [76,77].”
Acute cannabis intoxication among the paediatric population
Malta, G., Albano, G. D., Lavanco, G., Brancato, A., Cannizzaro, C., Argo, A., Contorno, S., Plescia, F., & Zerbo, S. (2025) · Frontiers in Toxicology · doi:10.3389/ftox.2025.1558721 · Cited by 19
Hoch, E., Krowartz, E., Hollweck, R., Möckl, J., & Olderbak, S. G. (2025) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2025.0161 · Cited by 17
Self-citationŠoša, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178635 · Cited by 9
Multi-Modal Cannabis Use Among U.S. Young Adults: Findings from the 2022 and 2023 BRFSS in 23 States
Kim, N., Flora, S. M., & Macander, C. (2025) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph22040495 · Cited by 6
“Alternatively, multi-modal cannabis use may exacerbate physical health problems, as increased exposure to cannabis could have adverse health effects, particularly among individuals with pre-existing physical conditions [45].”
Product features for promoting top-selling cannabis vape products in an online retail environment
Chen-Sankey, J. C., Capria, K. L., Meng, S., Mazzeo, R., Vijayakumar, N., Padon, A. A., Wagoner, K. G., Moran, M. B., Rossheim, M. E., Berg, C. J., et al. (2025) · Addiction Research & Theory · doi:10.1080/16066359.2025.2519601 · Cited by 7
“…products, may have potential applications for acute symptom relief across multiple conditions (e.g. anxiety, depression, epilepsy, pain); however, they also pose physical and mental health risks along with negative social consequences (National Academies of Sciences 2017; Hoch et al. 2025).”
The Pharmacology of Cannabinoids in Chronic Pain
Cortez-Resendiz, A., Leiter, T., Riela, S., Graziane, N., Raup‐Konsavage, W. M., & Vrana, K. E. (2025) · Medical Cannabis and Cannabinoids · doi:10.1159/000543813 · Cited by 13
“Acute intoxication can also lead to anxiety, distorted perceptions (paranoia, hallucinations, delusions), and physical health risks (including cannabis hyper-emesis syndrome) [59, 105].”
Motherhood and medicinal cannabis
Withanarachchie, V., Rychert, M., & Wilkins, C. (2025) · Drug and Alcohol Review · doi:10.1111/dar.14027 · Cited by 8
“Occasional use may also cause temporary cognitive impairment affecting motoric coordination increasing the risk of vehicle accidents [50].”
de Souza, M. L., Paiva, J. P. B., Franco, G. D. R. R., Gontijo, V. S., Alves, M. A., de Souza, H. M. R., Lontra, A. C. P., OLIVEIRA, E. A., Giorno, T. B. S., Guedes, I. A., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050755 · Cited by 5
“However, there are some limitations, such as psychoactive effects, limiting the clinical utility of CB1 agonists; legal and regulatory constraints still impact research and therapeutic use, and limited data exist concerning long-term safety [36].”
Li, Z., Lee, S., & Kannan, K. (2025) · Journal of Chromatography A · doi:10.1016/j.chroma.2025.466461 · Cited by 6
Cannabis use in youth is associated with chronic inflammation
Power, E., Mongan, D., Healy, C., Susai, S. R., Föcking, M., Zammit, S., Cannon, M. D., & Cotter, D. (2024) · Psychological Medicine · doi:10.1017/s0033291724002848 · Cited by 5
“…observational studies have recorded excessive morbidity and mortality associated with cannabis use disorder; however, a causal relationship between cannabis use and excessive mortality is questioned by some authors (Calabria, Degenhardt, Hall, & Lynskey, 2010; Hoch et al., 2024; Weye et al., 2020).”
Chung, D.-J., Chen, S.-P., Liu, W.-H., Liu, C.-Y., Su, N., Hsu, C., Tsai, H.-Y., Yang, K.-C., Wu, C., Lin, S.-W., et al. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01214-5 · Cited by 4
Cannabis Use Disorder in the Era of Legalization: Implications for Addiction Treatment Systems
Bahji, A. (2026) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s581271 · Cited by 6
Mashayekhi‐Sardoo, H., Hedayati‐Moghadam, M., & Baghcheghi, Y. (2025) · NeuroToxicology · doi:10.1016/j.neuro.2025.02.006 · Cited by 7
Hoch, E., Hall, W., & Feingold, D. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-01972-7 · Cited by 5
“Hoch and colleagues [5] explore the evidence on the negative health effects of recreational cannabis use and the safety and effectiveness of medicinal cannabis use.”
Self-citationBarré, T., Beo, V. D., Protopopescu, C., Lahaie, E., Andler, R., Nguyen‐Thanh, V., Pasquereau, A., Carrieri, P., & Beck, F. (2025) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2025.100381 · Cited by 4
“It has been associated with impairments in cognition and motivation, as well as with mood and psychotic disorders (Hoch et al., 2024).”
Lawley, S., Green, A. R., Johnson, C., & Burton, M. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00806 · Cited by 5
“The minimal but functionally significant population of CB1R-positive neurons in the hindbrain and their role in regulating interactions between the autonomic nervous system and the perception of pain warrant further investigation.”
Differentiation of Therapeutic and Illicit Drug Use via Metabolite Profiling
Stoeva, S., Hvarchanova, N., Gancheva, S., Eftimov, M., Georgiev, K., & Radeva-Ilieva, M. P. (2025) · Metabolites · doi:10.3390/metabo15110745 · Cited by 7
Freeman, T. P., Lees, R., Wadsworth, E., Carney, T., Castillo‐Carniglia, Á., Cerdá, M., Kalayasiri, R., Kilmer, B., Lorenzetti, V., Manthey, J., et al. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00087-8 · Cited by 11
Self-citationAge–period–cohort analysis of past 12‐month cannabis use in Germany (1995–2021)
Schöllner, N., Glos, A., Möckl, J., Krowartz, E., Hoch, E., & Olderbak, S. G. (2025) · Addiction · doi:10.1111/add.70087 · Cited by 2
“…with the daily or heavy use of cannabis, including respiratory and cardiovascular disorders, cognitive alterations, psychosis and schizophrenia [4], this trend poses potentially significant challenges for society and public health, necessitating a better understanding of the factors that…”
Self-citationStrada, L., Korteling, S., Vergeer, M., & Oomen, P. E. (2025) · Journal of Cannabis Research · doi:10.1186/s42238-025-00355-y · Cited by 5
“Although evidence for the effectiveness of cannabis in managing physical health conditions is growing, data on its efficacy for mental health conditions remains limited [33–35].”
Zolotov, Y., Edelstein, O. E., Temple, L. M., et al. (2025) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2025.103172 · Cited by 3
El‐Hammadi, M. M., Small-Howard, A. L., Arévalo, M. F., Turner, H. C., & Martín‐Banderas, L. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125766 · Cited by 5
Rescheduling Cannabis—Medicine or Politics?
Madras, B. K., & Larkin, P. J. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.1116 · Cited by 2
“Medical Cannabis”: Advising Patients While Navigating Medical Ethics and Limited Evidence
South, A.-M., Babalonis, S. L., Fanucchi, L. C., & Lofwall, M. R. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09680-7 · Cited by 2
Medical cannabis legalization and the use of illicit drugs, alcohol, and tobacco
Hallaj, H. A., & Barakat, Z. (2025) · Journal of Cannabis Research · doi:10.1186/s42238-025-00324-5 · Cited by 2
“Frequent users may develop tolerance, which in turn influences patterns of co-use (Hoch et al. 2024).”
InfluentialRajput, J., Narahari, S., Arif, T., Iftikhar, R., Arpan, T., Tariq, A., Duleh, H. M. A., & Cherukuri, S. (2025) · Cureus · doi:10.7759/cureus.92793 · Cited by 4
Beyond potency: A proposed lexicon for sensory differentiation of Cannabis sativa L. aroma
Isaacson, S. E., Wilson‐Poe, A. R., Ye, T., Qian, Y. L., & Shellhammer, T. H. (2025) · PLoS ONE · doi:10.1371/journal.pone.0335125 · Cited by 2
“Because THC poses dose-dependent health risks such as driving impairment, cannabinoid hyperemesis, and acute psychosis, the conflation of perceived quality with THC potency poses significant public health risks, and novel markers of product quality are warranted [11].”
Cannabis use in chronic pancreatitis: A narrative review
Javidi, D. J., & Gardner, T. B. (2025) · Pancreatology · doi:10.1016/j.pan.2025.12.017 · Cited by 2
Personalized pain management: The use of pharmacogenomics in pain treatment strategies
Scott, E. N., Simonson, L., & Loucks, C. M. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0304 · Cited by 4
Park, J.-H., Kim, D.-Y., Na, H.-H., Kwon, T.-H., Park, J.-S., Oh, Y. T., & Kim, K. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.03.051 · Cited by 3
Withanarachchie, V., Rychert, M., & Wilkins, C. (2025) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2025.2476989 · Cited by 2
Natural Compounds That Target Glioma Stem Cells
Yaroshenko, M., Christoff, M., Ścibiorski, M., Surowiec, K., Jakubowicz-Gil, J., & Sumorek-Wiadro, J. (2025) · NeuroSci · doi:10.3390/neurosci6020052 · Cited by 3
“Can be addictive and intoxicating (depending on the type—THC or CBD) and can cause psychiatric, gastrointestinal, and cardiovascular problems [85,86].”
Montemayor, B. N., Merianos, A. L., Bergeron, C. D., Sherman, L. D., Jacobs, W., Chung, S. Y., Hassan, A., & Smith, M. L. (2025) · Journal of Community Health · doi:10.1007/s10900-025-01500-7 · Cited by 2
“The use of cannabis in this context often occurs without consistent oversight, leaving users vulnerable to misinformation, potential drug-canna - bis interactions [ 50 , 51 ], unregulated product variability, increasing THC potency [ 52 ], and co-use with other sub - stances [ 50 ].”
Impact of legalization on cannabis exposure calls to the British Columbia Poison Control Centre
Trieu, J., Dobbin, N. A., Henderson, S. B., & McVea, D. A. (2025) · Canadian Journal of Public Health · doi:10.17269/s41997-025-01022-8 · Cited by 2
Recreational Marijuana Laws and Workplace Absence
Brown, M. (2026) · Health Economics · doi:10.1002/hec.70142 · Cited by 1
Phillips, K. T., Pedula, K. L., Tsuzaki, K., Erickson, C., Lai, J., Simiola, V., Wong, S., Pokhrel, P., & Satre, D. D. (2025) · Cannabis · doi:10.26828/cannabis/2025/000303 · Cited by 1
“Use of high-potency THC and dabbing, or inhaling concentrated cannabis extracts, can increase the risk of cannabis use disorder (CUD) and psychiatric effects, such as psychosis (Arterberry et al., 2019; Hoch et al., 2025).”
Cannabis and Health: Exploring Risks, Benefits and Research Horizons
Punniakotti, M., Ahmad, R., Villanueva, J., Roy, T., Mohammed, K., Sani, D., Mohammad, S., Sundaram, M., Haque, M., & Rahman, S. (2025) · Advances in Human Biology · doi:10.4103/aihb.aihb_134_25 · Cited by 1
Cannabis and Sudden Cardiac Death: A Case Series with Narrative Literature Review
Goffredo, V. M., Ferrara, M., Calvano, M., Pascale, N., Fazio, A. D., & Bertozzi, G. (2025) · Forensic Sciences · doi:10.3390/forensicsci5040052 · Cited by 1
“Cannabis is the most widely used illicit substance globally, especially among adolescents and young adults, with a growing trend linked to progressive legalization for both recreational and therapeutic use [1,2].”
Integrative network analysis reveals organizational principles of the endocannabinoid system
Shridhar, A., Dixit, S. M., Torres, A., & Gaudino, R. (2026) · Journal of Cannabis Research · doi:10.1186/s42238-026-00447-3 · Cited by 1
“…(Δ 9 -THC) and cannabidiol (CBD), derived from medical cannabis, interact with and modulate the activity of cannabinoid receptors, specifically CB 1 and CB 2 , influencing endocannabinoid signaling and therapeutic outcomes (Blebea et al. 2024; Mick and Douek 2024; Hoch et al. 2025).”
Nali, M. C., Larsen, M. Z., Li, Z., Li, J., Taylor, C. L., Dubrow, G. A., Wolpert, B. J., Trice, C., & Mackey, T. K. (2025) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2025.108183 · Cited by 1
Adverse events and cannabinoid use in cancer management: systematic review
Sosorburam, T. (2025) · BMJ Supportive & Palliative Care · doi:10.1136/spcare-2025-005759 · Cited by 1
“25 Significantly, the number of distinct AEs reported ranged widely—from as few as 1 to more than 12— raising concerns about heterogeneity in AE detection and reporting practices.”
Nadiradze, A., Khetsuriani, K., Talakvadze, T., Gulbani, M., Ratiani, E., Nebieridze, A., Gaprindashvili, N., Tabagari, N., Lunze, K., & Nadareishvili, I. (2025) · Journal of Primary Care & Community Health · doi:10.1177/21501319251394522 · Cited by 1
Choi, N. G., & Marti, C. N. (2025) · Traffic Injury Prevention · doi:10.1080/15389588.2025.2587850 · Cited by 1
“High-THC (tetrahydrocannabinol) consumption can cause acute mental, gastrointestinal, and cardiovascular problems and contribute to crashes (Hoch et al. 2025).”
Strada, L., van Gelder, N., Martinelli, T. F., et al. (2025) · Harm Reduction Journal · doi:10.1186/s12954-025-01369-8 · Cited by 1
“Despite more than two decades of legal availability and a growing body of evidence supporting the therapeutic use of cannabis [17, 57–61], our interviews revealed that prescribed cannabis continues to be a stigmatized medicine within both the healthcare system and broader societal context.”
Li, X., Wen, L., Du, Y. J., Fan, X., Xue, N., & Qu, M. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1731738 · Cited by 2
Substance Use Disorders and the Psychosis Spectrum: Assessment, Clinical Challenges and Management
Paparrigopoulos, T. J., Mellos, E., & Tzagarakis, C. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041562 · Cited by 3
“The strongest evidence indicates that cannabis can precipitate psychosis in individuals at elevated risk and may accelerate the transition from a prodromal phase to a first psychotic episode [58].”
Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies
Afonso, S., Gonçalves, J., Brinca, A. T., Rosendo, L. M., Rosado, T., Duarte, A. P., & Gallardo, E. (2026) · Diseases · doi:10.3390/diseases14020083 · Cited by 3
“Still, potential https://doi.org/10.3390/diseases14020083 side effects, such as liver toxicity and drug interactions, as well as inadequate regulatory oversight of CBD products, may constitute legitimate concerns [5].”
InfluentialHicks, B. M., Price, A. M., Whittington, B. J., Goldman, P., & Ilgen, M. A. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113323 · Cited by 2
Substance Abuse, Part A: Drugs and Alcohol
Cumming, M. (2026) · Springer eBooks · doi:10.1007/978-3-031-90919-1_36-1 · Cited by 1
Hu, M., Chen, H., Hu, D., Zhang, Y., & Guo, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1797092 · Cited by 1
“Cannabis use disorders, by contrast, involve mild modulation of the endocannabinoid system, characterized by slow dependence development, minimal acute physiological toxicity, and low direct mortality (Hall and Degenhardt, 2014; Weinstein and Gorelick, 2011; Hoch et al., 2025).”
Vasconcelos, Q. D. J. S., de Freitas, R. F., Freitas, M. C., de Andrade, I. P., Brandão, C. B., do Nascimento, C. E. M., Neves, K. R. T., Magalhães, P. S., Filho, V. B., Oliveira, G. L., et al. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111697 · Cited by 3
Murphy, E., Suo, C., Poudel, G., Thomson, H. M., & Lorenzetti, V. (2026) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s584766 · Cited by 1
Self-citationTudorancea, I. M., Filipiuc, L.-E., Vieru, D. S., Dobre, C.-E., & Tamba, B.-I. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1794928 · Cited by 3
“The molecular architecture of the ECS is defined by the presence of the CB1R and CB2R, together with their endogenous ligands, most notably AEA and 2-AG (Haspula and Clark, 2020).”
InfluentialCannabinoids and opioid consumption in cancer pain: a systematic review and meta-analysis
Creangă-Murariu, I., Alexa‐Stratulat, T., Rusu, M. I., Chiru, S., Dascalu, C., Dobre, C.-E., & Tamba, B.-I. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-10856-y · Cited by 2
“Expectancy effects may further contribute, as cannabinoids are associated with strong patient beliefs regarding analgesia and opioid substitution, potentially influencing self-management behaviors and symptom reporting; however, such effects are attenuated in blinded placebo-controlled trials [38].”
Śniadach, J., Szymkowiak, S., Osip, P., Orlof, W., & Waszkiewicz, N. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1778831 · Cited by 1
Skumlien, M., Greenwood, L., Arun, A. H., Goodwin, I., Paloubis, A., Rana, T. T., Quinones‐Valera, M., McTavish, E., Abbott, G., Dunsford, S., et al. (2026) · Addiction · doi:10.1111/add.70492 · Cited by 1
Self-citationBack to the roots: Cannabis sativa L. root metabolism, microbiomes, and biotechnological potential
Libik‐Konieczny, M., Hordyńska-Tomsia, N., Mazur, Z., Zieliński, K., Bibro, M., Kurczab, J., Gerszberg, A., Hnatuszko-Konka, K., Supel, P., Waligórski, P., et al. (2026) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-026-13955-2 · Cited by 1
“Despite ongoing debate surrounding the efficacy, safety, and legal status of cannabinoid-based products, their use and commercial relevance in the pharmaceutical industry continue to expand (Hoch et al. 2025).”
Sociodemographic Trends in Daily, Weekly and Less Than Weekly Cannabis Use in Australia
Leung, J., Chan, G., Zhang, R., Hall, W., & McClure‐Thomas, C. (2026) · Drug and Alcohol Review · doi:10.1111/dar.70207 · Cited by 1
Self-citationCannabis: multigenerational and food chain impacts
Reece, A. S., & Hulse, G. K. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-02003-1
“The authors have impressively summarized several complex literatures and skilfully distilled concise and pointed summaries [1].”
From relief to risks: a comprehensive review of medical cannabis
Lokhande, N., Mokal, A., Deshmukh, N. N., Borkar, A., & Patil, S. (2025) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20251740
Therapeutic Use of Cannabis: Knowledge and Acceptance among Citizens of Trujillo, Peru
Gómez-Amaya, V., Casanova-Coral, A., Campaña-Silva, J., Cubas-Namó, J., Namay-Rebaza, J., Camacho-Narvayes, G., & Rojas-Villacorta, W. (2025) · F1000Research · doi:10.12688/f1000research.165597.1
Candeloro, B. M., OLIVEIRA, N., Franchi, A. C., Chagas, A. D. S., Gonzaga, L. A., Raimundo, R. D., Barbalho, S. M., Porto, A. A., Garner, D. M., & Valenti, V. E. (2025) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-025-00680-6 · Cited by 4
“As cannabinoid-based therapies expand into clinical practice, recent reviews have called attention to the disproportionate emphasis on neurological indications, leaving cardiovascular disease underexplored (Hoch et al. 2025).”
Hazimeh, B., Bou-Orm, I. R., Mroueh, M. A., et al. (2025) · Lebanese Journal of Mental Health · doi:10.4103/ljmh.ljmh_17_25
Consumo de cannabis en población adulta de España (2022)
Teijeiro, A., Guerra-Tort, C., Casal-Fernández, R., Gisbert, L. M., García, G., Varela‐Lema, L., & Pérez‐Ríos, M. (2025) · Gaceta Sanitaria · doi:10.1016/j.gaceta.2025.102524
Withanarachchie, V., Wilkins, C., Parker, K., et al. (2025) · Drug and Alcohol Review · doi:10.1111/dar.70063
Associations between cannabis use and self-rated quality of life among adults in the United States
Nabil, A. K., Montemayor, B. N., & Barry, A. E. (2025) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2025.2581696
“It should be noted, however, ‘the evidence is inconclusive on their [cannabis and cannabinoids] value in treating mental disorders and other medical conditions’ (Hoch et al., 2025) and ‘long-term marijuana use can lead to addiction’ (Volkow et al., 2014).”
Janda, A., Rosiewicz, M., Durowicz, M., Górnicka, I., Pastuszek, A., Bieńkowska, K., Drzymała, J., Kierepka, U., & Bartolik, S. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4101
Clemente, G., Oliveira, C. V. D. S., da Hora, M. F. V. M. P., Miranda, E. S., Osorio-de-Castro, C. G. S., Esher, Â., & Santos-Pinto, C. D. B. (2025) · Saúde em Debate · doi:10.1590/2358-2898202514710408p · Cited by 1
The endocannabinoid system: role in skeletal muscle and regenerative myogenesis
Falsetti, I., Donati, S., Marini, F., Iantomasi, T., Margheriti, L., Moro, A., & Palmini, G. (2025) · International Journal of Bone Fragility · doi:10.57582/ijbf.250503.089
Chávez-López, M. D. G., Ávalos‐Fuentes, A., Cruz-Manzo, E. D. C., Aguirre-Arriaga, P. A., Florán, B., Pérez‐Carreón, J. I., Bañuelos, C., & Camacho, J. (2026) · Pathophysiology · doi:10.3390/pathophysiology33010008
“Emerging evidence on cannabinoid uses in diverse medical settings including oncology [203,204] coexists with heterogeneous public perceptions and, in some contexts, with stigma or misinformation.”
Poczwardowski, T., Kaczmarek, A., Szweda, F., Augustyniak, K., Chwalczuk, M., Latos, J. T., Grygorcewicz, O., Koneczna, M., Kowalska, K. A., & Krystyniak, K. A. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4603
O konopiach w farmacji. Historia sprzed odkrycia tetrahydrokannabinolu – THC
Księżopolski, R. (2026) · Medycyna Nowożytna · doi:10.4467/12311960mn.25.037.22724
Chauhan, A. N. S., Dalvi, O. S., & Erande, R. D. (2026) · Tetrahedron Letters · doi:10.1016/j.tetlet.2026.155978
Rahman, A. B., Naserrudin, N. A., Seman, Z., Zin, Z. M., Dapari, R., Hassan, M. R., Rashid, A. A., Dahaban, M. U. M., Jahaya, N. H., Sheikh, S. A., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-104802
Bakhtiari, R., Tomczak, M. V., Langor, S. D., Granley, A., Campbell, F. N., & Singhal, A. (2026) · OBM Geriatrics · doi:10.21926/obm.geriatr.2601334
Leyde, S. E., Merrill, J. O., Treadway, A., Pike, K. C., & Price, C. J. (2026) · Substance Use & Addiction Journal · doi:10.1177/29767342251401312
Urine Drug Testing: Service Models and Laboratory Practices to Meet Clinical Care Needs
Stefan, C., Jung, B., Zhou, J. R., et al. (2026) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001428
Bae, H. T., & Kerr, D. C. R. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113127
Guillem, E., Verneuil, L., & Bayle, F. (2026) · L Encéphale · doi:10.1016/j.encep.2025.12.009
Does medicinal cannabis work for depression, anxiety or PTSD? Our study says there’s no evidence
Wilson, J., & Stockings, E. (2026) · doi:10.64628/aa.tfwh5wstg
Merrill, R. M., Palmer, J. C., & Larson, H. (2026) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph23040421
“A recent review has summarized current evidence on risks and medical benefits of cannabis, cannabinoids, and health [10].”
Carlini, B. H., Kellum, L. B., Garrett, S. B., & Williams, J. R. (2026) · Substance Use & Addiction Journal · doi:10.1177/29767342261426116
From controversy to clinical evidence: the evolving role of cannabis in pain therapy
Demann, R., Bonnet, U., Juckel, G., et al. (2026) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-026-02225-x
Self-reported Visual Function After Non-medical Cannabis Use: A Cross-sectional Survey
Elmadina, A. E. M., & Hagar, S. I. E. (2026) · Sudan Journal of Medical Sciences · doi:10.18502/sjms.v21i1.19228
Weng, M., Zheng, Q., Ratsch, A., et al. (2026) · Journal of Chromatography B · doi:10.1016/j.jchromb.2026.125051
Jacques, Q., Gao, Z., Najafizada, M., Bishop, L. D., Howells, R., & Donnan, J. R. (2026) · Journal of Drug Education · doi:10.1177/00472379261439959
Zamanian, N., Mohajerani, A., Barkhordar, M., Rahimlou, M., Khosroshahi, R. A., Talebi, S., Azari, M., Soleimani, A., & Mohammadi-Kangarani, H. (2026) · Nutrition and Cancer · doi:10.1080/01635581.2026.2652000 · Cited by 1
“Our high heterogeneity likely stems from short trial durations and small samples, as subgroup results showed appetite improvements only in 6-week studies perhaps an artifact of placebo effects or early symptomatic responses rather than sustained metabolic shifts (61).”
Meckes, S. J., Kelley, V., Calhoun, P. S., & Dennis, P. A. (2026) · Community Mental Health Journal · doi:10.1007/s10597-026-01626-5
Recent Advances in Sustainability Assessment of Medicinal Cannabis Cultivation and Production
Labjouj, H., Joumri, L. E., Labjar, N., Benabdallah, G. A., Elouaham, S., Nasrellah, H., Bihadassen, B., Labjar, H., Ouardi, E. A. E., & Hajjaji, S. E. (2026) · Clean Technologies · doi:10.3390/cleantechnol8030060
Psychometric evaluation of the perceived barriers to cannabis reduction and cessation scale
Buckner, J. D., Jo, D., Shepherd, J. M., Clausen, B. K., Garey, L., & Zvolensky, M. J. (2026) · Addictive Behaviors · doi:10.1016/j.addbeh.2026.108728 · Cited by 1
Abbott, G., Greenwood, L., Bartschi, J. G., Verdejo-García, A., Solowij, N., & Lorenzetti, V. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07072-1
Self-citationCannabis Legalization and Public Health Outcomes: Scoping Review with ☸️SAIMSARA
SAIMSARA (2026) · SAIMSARA Journal · doi:10.62487/saimsara19c0132a
Sarma, K., Akhter, M. H., Rab, S. O., Aljadaan, A. M., Emwas, A.-H. M., & Jaremko, M. (2026) · Open Chemistry · doi:10.1515/chem-2025-0211
“Thus, amalgamated nanocarriers loaded with therapeutic agents improve the e ffi cacy of drugs in the treatment of lung cancer, where access to targeted therapy is especially important [8, 11 – 16].”
InfluentialMurphy, E., Poudel, G., Dakhili, A. H., Ganesan, S., Zalesky, A., Glarin, R., Thomson, H. M., Lin, S. C., Paloubis, A., Kamboj, S. K., et al. (2026) · Addictive Behaviors · doi:10.1016/j.addbeh.2026.108741
Self-citationWhat sleep physicians need to know about cannabis use for sleep
Velzeboer, R., & Lai, W. W.-K. (2026) · Journal of Clinical Sleep Medicine · doi:10.1007/s44470-026-00095-7
“Compared with THC, CBD appears to have a better safety profile, particularly with respect to intoxication and psychosis, though it is not risk-free [23].”
U.S. Poison Center exposure cases involving marijuana and selected comparator substances
Karami, S., Radin, R., Greene, C. R., et al. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113204
Metadata
- Authors
- Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W.
- Affiliations
- LMU Klinikum (DE)
- National Institute on Alcohol Abuse and Alcoholism (US)
- IFT Institut für Therapieforschung (DE)
- Australian Catholic University (AU)
- University of Bath (GB)
- The University of Queensland (AU)
- Corresponding author
- Hoch, E.
- Venue
- European Archives of Psychiatry and Clinical Neuroscience
- Published
- 2024-09-19
- Volume
- 275
- Issue
- 2
- Pages
- 281-292
- ISSN
- 0003-9373 (ISSN-L)
- 0940-1334
- 1433-8491
- PMC
- PMC11910417
- OpenAlex
- W4402698048
- Semantic Scholar
- 04009c33b5339cffb27ec4198594652c85a4294d
- Cited by
- 139
- References
- 119
- Citations by year
- 2026: 86 · 2025: 52 · 2024: 1
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- European Archives of Psychiatry and Clinical Neuroscience (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion, cc-by)
- Funders
- Klinikum der Universität München
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- cannabis, cannabinoids, delta-9-tetrahydrocannabinol, recreational cannabis use, medical cannabis, cannabis use disorder, adolescent cannabis use, psychosis, schizophrenia, cognitive impairment, prenatal cannabis exposure, cannabidiol, chronic pain, epilepsy, chemotherapy-induced nausea and vomiting, cannabis legalization
- MeSH terms
- Cannabinoids, Cannabis, Marijuana Abuse, Humans, Dronabinol, Medical Marijuana
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.